InsiderTrades.com logo
CNBC’s ‘Prophet’ issues urgent Fed warning
From Stansberry Research   |   Ad
"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."
Click here now to watch this exclusive interview

PMN Insider Trading

Insider Ownership Percentage: 6.39%
Insider Buying (Last 12 Months): $177,100.00
Insider Selling (Last 12 Months): $0.00

ProMIS Neurosciences Insider Trading History Chart

This chart shows the insider buying and selling history at ProMIS Neurosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ProMIS Neurosciences Share Price & Price History

Current Price: $1.30
Price Change: ▲ Price Increase of +0.07 (5.69%)
As of 09/24/2024 01:00 AM ET

This chart shows the closing price history over time for PMN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
CNBC’s ‘Prophet’ issues urgent Fed warning
From Stansberry Research   |   Ad
"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."
Click here now to watch this exclusive interview

ProMIS Neurosciences Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/23/2024Madge K ShafmasterDirectorBuy70,000$1.28$89,600.00138,333View SEC Filing Icon  
9/20/2024Madge K ShafmasterDirectorBuy60,000$1.25$75,000.0068,333View SEC Filing Icon  
8/14/2024Patrick D KirwinDirectorBuy10,000$1.25$12,500.0062,983View SEC Filing Icon  
See Full Table
CNBC’s ‘Prophet’ issues urgent Fed warning
From Stansberry Research   |   Ad
"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."
Click here now to watch this exclusive interview

SEC Filings (Institutional Ownership Changes) for ProMIS Neurosciences (NASDAQ:PMN)

50.13% of ProMIS Neurosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

ProMIS Neurosciences Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/7/2024Ieq Capital LLC30,799$35K0.0%-21.4%0.163%Search for SEC Filing on Google Icon
11/15/2023Affinity Asset Advisors LLC265,958$0.53M0.1%N/A3.100%Search for SEC Filing on Google Icon
11/15/2022Northeast Financial Consultants Inc100,000$0.61M0.0%N/A1.166%Search for SEC Filing on Google Icon
11/4/2022Ieq Capital LLC39,191$0.24M0.0%N/A0.457%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
ProMIS Neurosciences logo
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Read More on ProMIS Neurosciences

Today's Range

Now: $1.30
Low: $1.22
High: $1.32

50 Day Range

MA: $1.41
Low: $1.20
High: $2.15

52 Week Range

Now: $1.30
Low: $0.95
High: $3.10

Volume

106,909 shs

Average Volume

70,907 shs

Market Capitalization

$24.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62

Who are the company insiders with the largest holdings of ProMIS Neurosciences?

ProMIS Neurosciences' top insider investors include:
  1. Madge K Shafmaster (Director)
  2. Patrick D Kirwin (Director)
Learn More about top insider investors at ProMIS Neurosciences.
CNBC’s ‘Prophet’ issues urgent Fed warning
From Stansberry Research   |   Ad
"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."
Click here now to watch this exclusive interview